In cartilage tissue engineering from MSCs, hypertrophy poses formidable challenges. Hypertrophy is a process characterized by an increase in the cell size and appearance of typical markers such as type X collagen, preparing cells for apoptosis. Hypertrophy itself is a landmark for correct chondrocyte differentiation, representing the normal fate of chondrocytes during the developmental process with the exception of the AC. We have previously demonstrated that PD98059 suppressed hypertrophy in the chondrogenesis from hMSCs and hASCs as demonstrated by the decrease of type X collagen and Runx-2 at both mRNA and protein level, and that PD98059 promoted chondrogenesis as shown by the accumulation of GAG and an increase of type II collagen. As this small molecule is more stable and easier to apply than peptide growth factors, PD98059 can be impregnated in the porous scaffolds, and further evaluated as a chondrogenic and anti-hypertrophic factor in the direct tissue engineering from MSCs. The aim of this study was to develop and test the usefulness of the PD98050-impregnated functional chondrogenic scaffold that serves as a successful carrier of MSCs and suppress hypertrophy in direct cartilage tissue engineering. The effectiveness of this functional scaffold was compared with a scaffold immobilized with TGF-β 2 which has been known to induce chondrogenic differentiation from MSCs. Methods: PD98059-loaded PLGA/F127 scaffolds were fabricated by a melt-molding particulate-leaching method. TGF-β 2 was also incorporated onto the pore surfaces of the PLGA/F127 scaffold via heparin immobilization. The in vitro chondrogenesis of hMSCs from TGF-β 2 -immoblized or PD98059-impregnated PLGA scaffold was compared with that of the PLGA scaffolds without any growth factor as a control. After autologous rMSCs adhesion to each PLGA scaffold, the cell-scaffold composites were implanted in a large osteochondral defect that was created in the patellar groove of the distal femur of the rabbit left knee. Results: PD98059-impregnated PLGA scaffold is fabricated and compared with TGF-β 2 -immobilized scaffold. The PD98059 is continuously released from the scaffolds over 140 days in contrast to the rapid release in TGF-β 2 -immobilized scaffold. The in vitro culture results show that the PD98059-impregated scaffold is more effective in suppressing hypertrophy than the TGF-β 2 -immobilized scaffold while both scaffolds enhance chondrogenesis from hMSCs. After 10 weeks of in vivo implantation in rabbits, the osteochondral defects is successfully repaired in both PD98059-impregnated and TGF-β 2 -immobilized scaffold seeded with rMSCs when evaluated grossly and microscopically. However, type X collagen is not observed from regenerated cartilage in PD98059-impregnated scaffold while it is detected around chondrocytes in the TGF-β 2 -impregnated scaffolds. In addition, the PD98059-impregnated scaffold has better reconstitution of the subchondral plate. Discussion: These results suggest that the use of the PD98059-impregnated scaffold led to AC regeneration of better quality than the TGF-β 2 -immobilized scaffold and prevented hypertrophy when implanted in the osteochondral defects of rabbits. It can be asserted that the PD98059-impregnated functional scaffold is very effective for cartilage regeneration using MSCs and holds considerable promise as a tool for direct cartilage tissue engineering. Significance: As PD98059 is more stable and easier to apply than peptide growth factors such as TGF-beta, this can be impregnated in the porous scaffolds, and further evaluated as a chondrogenic and anti-hypertrophic factor in the direct tissue engineering from MSCs.
